OncoMatch/Clinical Trials/NCT05351346

Genotype-guided Treatment in DLBCL

Is NCT05351346 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for diffuse large b cell lymphoma.

Phase 3RecruitingRuijin HospitalNCT05351346Data as of May 2026

Treatment: Rituximab · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone · Orelabrutinib · Lenalidomide · Decitabine — A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Previous chemotherapy.

Cannot have received: stem cell transplant

Previous stem cell transplantation.

Lab requirements

Blood counts

Neutrophils <1.5×10^9/L; Platelets <75×10^9/L (Platelets <50×10^9/L in case of bone marrow involvement)

Kidney function

Creatinine is 1.5 times higher than the ULN.

Liver function

ALT or AST is 2 times higher than the upper limits of normal (ULN), AKP and bilirubin are 1.5 times higher than the ULN.

Cardiac function

Left ventricular ejection fraction <50%

Laboratory measures meet the following criteria at screening (unless caused by lymphoma): 1. Neutrophils <1.5×10^9/L 2. Platelets <75×10^9/L (Platelets <50×10^9/L in case of bone marrow involvement) 3. ALT or AST is 2 times higher than the upper limits of normal (ULN), AKP and bilirubin are 1.5 times higher than the ULN. 4. Creatinine is 1.5 times higher than the ULN. Left ventricular ejection fraction <50%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify